Studies on human serum paraoxonase/arylesterase

https://doi.org/10.1016/0009-2797(93)90022-QGet rights and content

Abstract

The complete amino acid sequence of human serum paraoxonase/arylesterase and the DNA sequence coding for that protein have recently been determined in two independent laboratories. There is now considerable evidence that the esterase exists in two genetically determined allozymic forms, and these A and B allozymes possess both paraoxonase and arylesterase activities. The B-type esterase has relatively higher paraoxonase activity and is stimulated to a greater degree by 1 M NaCl than the A allozyme. The structural basis for the distinctive isozymic properties is a single nucleotide base at position 572. Codon 191 is CAA (for glutamine) in the A-type esterase, and CGA (for arginine) in the B-type enzyme. There is a second polymorphic site which affects amino acid 54; this can be either methionine or leucine, but these alternatives have not been found to affect either the level or the quality of the allozymes. Purified A or B-type esterases are stimulated by the addition of phosphatidylcholine. The latter addition increases the maximum velocity rate, but does not alter the Km of the reaction with either paraoxon or phenylacetate. In serum, the esterase is tightly bound to the high density lipoproteins, particularly apo A-1, but the importance of this association as far as the stability and catalytic properties of the esterase is not clear, and still under study. No physiological role of the esterase has been established, but its ability to hydrolyze several potent organophosphates may be of some significance in protecting against organophosphate toxicity.

References (15)

  • S. Adkins et al.

    Purification and cloning of human serum paraoxonase/arylesterase

    FASEB J.

    (1991)
  • C. Hassett et al.

    Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence

    Biochemistry

    (1991)
  • H.W. Eckerson et al.

    The human serum paraoxonase/arylesterase polymorphism

    Am. J. Hum. Genet.

    (1983)
  • M.I. Mackness et al.

    Distinction between ‘A’-esterases and arylesterases

    Biochem. J.

    (1987)
  • B.N. La Du

    Human serum paraoxonase/arylesterase

  • K.N. Gan et al.

    Purification of human serum paraoxonase/arylesterase, evidence for one esterase catalyzing both activities

    Drug Metab. Dispos.

    (1991)
  • A. Smolen et al.

    Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase

    Drug Metab. Dispos.

    (1991)
There are more references available in the full text version of this article.

Cited by (104)

  • Enhancement in the production of recombinant human paraoxonase 1 in Escherichia coli: A comprehensive approach of cellular engineering and optimization of protein folding process in vitro

    2022, International Journal of Biological Macromolecules
    Citation Excerpt :

    His 134 helps to increase the basicity of His 115 [7]. PON1 plays an important role in the protection against organophosphates such as parathion, chlorpyrifos [9] and nerve agents such as sarin and nerve V [10]. Along with this, PON1 also plays other roles in humans, such as prevention of atherosclerosis, LDL oxidation and other cardiovascular diseases [11].

  • Biotransformation of warfare nerve agents

    2020, Handbook of Toxicology of Chemical Warfare Agents
  • Biotransformation of Warfare Nerve Agents

    2015, Handbook of Toxicology of Chemical Warfare Agents: Second Edition
  • Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease

    2012, Neurobiology of Aging
    Citation Excerpt :

    PON1 and PON3 are found in serum whereas PON2 is primarily an intracellular enzyme (Stoltz et al., 2009). In vitro, paraoxonase activity in serum can be measured using colorimetric assays (Browne et al., 2007; Furlong et al., 1989; Nozawa et al., 1980) utilizing a variety of indicator substrates (La Du et al., 1993; Lockridge et al., 1980; Smolen et al., 1991) including thiobutyl butyrolactone (TBBL) and phenyl acetate (PA). The PA assay, which measures an arylesterase activity of paraoxonase, is a widely used assay but may not represent a native physiological activity (Khersonsky et al., 2006).

View all citing articles on Scopus
View full text